International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2770-2776 www.ijprajournal.com ISSN: 2456-4494

Preclinical Drug Safety Surveillance Foundation for Clinical Pharmacovigilance

Prof. (Dr.) Mohd.Wasiullah[1], Prof.(Dr.) Piyush Yadav[2], Asst.ProfSushil Yadav[3,] Girijesh Yadav[4*,]Roshan Yadav[5]

Date of Submission: 25-04-2025 Date of Acceptance: 05-05-2025

ABSTRACT:
The development of safe and efficient pharmaceuticals, vaccines, and medical devices depends on pharmacovigilance (PV) sciences, which encompass activities pertaining to safety surveillance of pharmaceutical goods. Preclinical research is the first step in safety monitoring, which continues during clinical trials and the post-marketing stages. PV scientists regularly monitor and analyze safety data to guarantee patient safety during clinical studies. The complexity of regulations has increased, resulting in approaches for evaluating big clinical trial safety datasets that are not well defined. Adverse drug responses (ADRs) or safety signals may go undetected as a result of inconsistent safety data review (SDR) procedures.This quality improvement effort standardized patient safety surveillance in clinical trials and created a Safety Data Review Handbook using the Plan Do Study Act (PDSA) methodology. It was developed based on input from PV scientists and existing pharmacovigilance laws. The perceived utility of employing a standardized approach and attitudes toward current procedures were assessed using a mixed methods analysis. SDR guidelines, work instructions, review checklists, and a training program were all included in the Handbook. To assess the experience level, present safety data review procedures, contentment with the current procedures, and interest in implementing standardized SDR guidelines, an anonymous survey was sent to PV scientists employed in the pharmaceutical sector. Interviews and focus groups were used to evaluate PV's requirements and difficulties.

Keywords: Risk/benefit analysis, clinical trials, pharmacovigilance, safety surveillance, quality improvement, risk management, adverse events, and patient safety.

I. INTRODUCTION

Pharmacovigilance is the scientific field concerned with detecting, assessing, and averting adverse drug reactions (ADRs) in order to protect patient safety. The term is derived from the Greek word "pharmacon" (medical substance) and the Latin word "vigilare" (to keep watch). Pharmacovigilance teams collaborate to make sure that a medicine's advantages balance its disadvantages at every stage of its lifecycle, from preclinical toxicological research to post-marketing research and actual drug use. Pharmacovigilance scientists (PVscientists), also known as clinical or drug safety scientists, are essential in evaluating safety data from clinical trials on a regular basis and making well-informed decisions to safeguard patient health. PV scientists include doctors, nurses, and pharmacists with a variety of clinical backgrounds. As stewards of drug safety, they are able to act thanks to their therapeutic knowledge and proficiency in the synthesis and interpretation of safety data. In order to find potential dangers and confounding factors, they examine adverse events (AEs) that happen during clinical trials both collectively and individually, taking into account important variables including the patient's medical history, the time to onset after a medicine was administered, and competing drugs. By identifying safety concerns early and communicating with stakeholders and regulatory bodies effectively, PV scientists' work protects trial participants. The growing amount of safety data that PV scientists see in contemporary clinical trials calls for standardized and effective data evaluation procedures. Methods of safety surveillance, however, can differ among clinical trial initiatives. This could result in a decline in data accuracy, safety monitoring consistency, and regulatory standard compliance. The prompt detection of safety signals may be hampered by a lack of standardization, which could jeopardize patient safety. The opinions of PV scientists regarding the safety data review procedures that are already in place, including any perceived gaps in the guidelines, and how to assist teams in conducting reliable and effective safety data reviews were

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2770-2776 www.ijprajournal.com ISSN: 2456-4494

investigated in this quality improvement project. This project sought to address issues by creating a Safety Data Review Handbook to streamline the safety data review procedure for PV scientists, based on a requirements assessment based on their comments.A guidance manual, checklists, job instructions, documentation templates, and training programs were among the reference materials included in this product. The goal was to streamline adverse event and patient data review to ensure consistency in data analysis across clinical trials.PV scientists were able to influence the instruments required to improve their safety monitoring techniques and patient safety by including safety physicians in the safety data review guidance document's development process. The pharmacovigilance cycle comprises the following steps: recognizing adverse events, notifying the health system, reporting the event using standard reporting methods and mechanisms, looking into the nature of the event, figuring out what caused it, and giving feedback to all cycle stakeholders. The data collected during this process is processed and carefully analyzed to look for unusual patterns. Communication also plays a key role in pharmacovigilance.

The ongoing review process for gathering, processing, and evaluating safety data from various sources is known as the pharmacovigilance cycle (Figure 1). The cycle necessitates the use of globally compliant regulatory processes and standardized methods for AE collection and reporting incidents to health systems. Analyzing occurrences entails looking into their nature and giving all parties involved comments. To reduce patient risk, the benefit-risk profile is regularly assessed and the data gathered during this procedure is closely examined for odd trends. Throughout the PV process, prompt and efficient communication with patients, healthcare providers, and regulatory bodies is essential.



Figure 1 :Pharmacovigilance Safety Data Review Cycle

The origin of the idea of pharmacovigilance:

Pharmacovigilance began as a field focused on identifying, assessing, preventing, and raising awareness of adverse drug reactions and other medication-related issues in the middle of the 1800s.The most crucial aspect of a public safety concern is gathering various data pertinent to a product's behavior, i.e., medication life cycles, both before and after the product is put on the market. One important aspect in this field of study is the unprompted reporting of adverse drug reactions (ADRs) by doctors or pharmacists. This helps prevent and treat a number of diseases. A brief review of previous drug-related incidents can help to clarify the importance of pharmacovigilance and give a clear picture of how the skill was developed. Over 160 years have passed since the inception of pharmacovigilance.when a commission was formed by The Lancet to encourage physicians from Britain and her colonies to monitor deaths caused by anesthesia. Prior to a normal in-growing toe nail removal, 15-year-old Hannah Greener passed away following her administration of chloroform, a novel anesthetic at the time15. Consequently, this

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2770-2776 www.ijprajournal.com ISSN: 2456-4494

monitoring system was a precursor to the current SRS16. In order to prevent the adulteration and misbranding of foods and medications that were then on the market, the United States passed the Federal Food and Drug Act in 1906. But in 193717, the use of diethylene glycol to dissolve sulfanilamide led to the deaths of more than a hundred persons. The 1938 Food, Drug, and Cosmetic Act was therefore made stricter. It prohibited deceptive commercial claims and ingredient misbranding. The most catastrophic drug-related incidentSimilar to this, a higher incidence of limb deformity in infants was noted in Australia, and the common denominator was the mothers' use of the novel hypnotic medication "thalidomide." In West Germany, where thalidomide was sold over-the-counter, the tragedy had the biggest effect. If the medication had been thoroughly examined in preclinical safety trials, a serious tragedy might have been prevented. The World Health Assembly requested that WHO establish a worldwide framework for monitoring adverse drug reactions (ADRs) based on data from national centers and develop appropriate procedures for monitoring ADRs, particularly late toxic effects, of already-in-use medications in light of the thalidomide tragedy in the early 1960s. These resolutions led to the establishment of a pilot project in Virginia, USA.A collaborating center was established with the kind assistance of the Swedish government to oversee the program's operational activities once the operational activities were moved to Uppsala, Sweden20. In a database with more than 9 million items, it maintains track of adverse effect records. As of March 10, 2021, over 150 countries had joined the WHO Drug Monitoring Programme, which started with ten member countries.

Pharmacovigilance is necessary.

Testing on animals Healthy, disease-free animals that are carefully selected, watched over, and fed until they are introduced to novel human goods are used in animal research. The general significance of these tests in the production of a medicine has long been disputed because of the varying potential to generalize results from animal studies to people. However, toxicity, which regrettably occurs when the medicine is administered in humans, has occasionally been missed by extensive studies. Animals cannot replicate many hazardous effects that have been seen in humans. Consequently, there is no way to fully anticipate human toxicity from experimental animal research.

Pre-clinical trial

Phase I through III clinical trials are carried out in tightly regulated environments, with close attention paid to both positive and negative outcomes. For a variety of reasons, extensive clinical testing frequently misses medication safety problems that surface after marketing.

- Although clinical study settings are closely watched, they don't always reflect the actual circumstances when patients are taking drugs. Only carefully chosen, generally safe patients with distinct symptoms are admitted to many studies, which are expressly intended to ascertain efficacy.
- There are limitations on the quantity of patients and duration of drug exposure. ADRs at a frequency of less than 1:100 are unlikely to be found because only a few hundred patients will be exposed. Clinical studies rarely examine long-term drug outcomes, and long-term reactions are often missed.
- Certain groups are not included, including the elderly, newborns, expectant mothers, and a range of sick individuals. The trial design may limit observation to specific metrics, like blood pressure and count, which could lead to the observation of events that are not part of the protocol (e.g., menorrhea, muscle soreness, or changes in vision).
- Both the researcher and the manufacturer (sponsor) may be biased during premarketing trials, with positive outcomes anticipated and negative effects disregarded or disregarded, with the exception of double-blind studies.

Under-reporting Globally, there is a notable underreporting of adverse drug reactions. Belton et al. claim that a lack of report forms, uncertainty about who and how to report, a lack of time, a fear of legal repercussions, or the perception of being foolish or inept are the main reasons why ADR reporting is declining in Europe. The next stage of drug development involves testing a medication on humans, known as clinical trials. The design and execution of these trials are greatly aided by preclinical safety data, which help establish safe parameters for human usage and offer insights into the drug's possible dangers.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2770-2776 www.ijprajournal.com ISSN: 2456-4494

Role of the health care professionals in pharmacovigilance:

Many health care professionals are not aware of how crucial it is that they help determine a drug's benefit-risk profile. In post-marketing situations, even when an adverse impact is established, the reporter has complete freedom over the details provided, with the exception of clinical studies, when guidelines for the medical information collected are specified by the maker and the trial protocols. This can lead to a lack of information, which would make it challenging to determine whether the administration of the medication is connected to the development of the adverse event. Additionally, regulators require "minimum" data to evaluate and report a case, which includes identifying the drug that was considered suspect, the patient (using an identifier such as "an elderly male patient" or "a caucasian female patient," but not needing to identify the patient by name), a drug product, a reporter, and the AE itself. There are still guidelines that require companies to follow up with an AE reporter in order to obtain sufficient data to make causal determinations. Although there are many regulations that businesses must follow globally, the International Conference on Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH) sets guidelines that have been specifically adopted or included in regulations by a number of authorities. For example, the usage of the ICH notion of a major adverse occurrence has been agreed upon by all parties involved. It's worth noting that this concept isn't always the same as what a clinician considers "severe" in terms of the patient's effects. The commonly recognized criteria for severity are found in ICH guideline E2A29. The majority of these identifiers dictate whether an adverse event report should be submitted on a regular basis, which is crucial in the pharmaceutical and regulatory sectors, or expeditedly, which typically entails within 15 days of receiving an AE (as part of an aggregate report that contains a collection of AE cases that may be submitted on a quarterly to annual basis).

Preclinical Safety Data: A Crucial Element in the Pharmacovigilance Lifecycle:

The process of drug development is a comprehensive and multi-stage endeavor aimed at bringing new therapeutics to market while ensuring patient safety. One of the most vital steps in this process is preclinical safety testing, which serves as the foundation for clinical pharmacovigilance and is critical to managing the safety of new drugs. Preclinical safety data helps identify potential risks, predict adverse reactions, and inform the design of clinical trials, thus playing a pivotal role in the pharmacovigilance lifecycle.

Pharmacovigilance refers to the ongoing monitoring, evaluation, and response to adverse drug reactions (ADRs) throughout a drug's life cycle. This process begins early in the drug development phase and continues throughout the clinical use of the drug. Preclinical safety data are gathered before human trials and form the cornerstone of pharmacovigilance, as they provide insights into the toxicity, pharmacokinetics, and pharmacodynamics of a new drug. These insights help predict potential adverse effects and determine appropriate monitoring and dosing strategies during clinical trials and post-marketing use.

In this paper, we will explore the critical role of preclinical safety data in the pharmacovigilance lifecycle, from its foundational importance in identifying early safety signals to its application in clinical and post-marketing surveillance. We will discuss how preclinical studies inform the design and execution of clinical trials, contribute to regulatory decision-making, and ultimately support ongoing safety monitoring in clinical practice.

Regulatory Approval and Decision-Making

Before clinical trials can begin, regulatory agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other global health authorities require a comprehensive investigation of preclinical safety data as part of the Investigational New Drug (IND) application. This submission includes detailed reports from toxicity, pharmacokinetic, and other preclinical studies.

The regulatory authorities evaluate preclinical data to determine whether a drug is safe to move forward into human testing. If preclinical data indicate significant safety concerns—such as toxicological issues, genotoxicity, or risks of carcinogenicity—the regulatory agency may request further studies, impose dose limitations, or reject the application entirely.

Moreover, preclinical safety data are instrumental in shaping the risk management strategies employed during clinical trials. The insights from animal studies help regulators establish risk mitigation measures such as limited patient enrollment, extra monitoring for specific

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2770-2776 www.ijprajournal.com ISSN: 2456-4494

adverse effects, or other precautions to minimize harm during human trials.

Post-Marketing Surveillance and Ongoing Monitoring

Even after a drug is approved and reaches the market, the pharmacovigilance process continues through post-marketing surveillance. Preclinical safety data help shape phase IV surveillance strategies, particularly in detecting long-term adverse events that may not have been observed in clinical trials.

Some risks, such as rare or delayed side effects, may not become apparent until a drug is used in the broader population over an extended period. Preclinical studies help anticipate these issues by highlighting areas of potential concern (e.g., reproductive toxicity, carcinogenicity, or rare organ toxicities). By referencing preclinical data, pharmacovigilance teams can remain vigilant in monitoring for such adverse effects once the drug is in use.

The data from clinical trials and post-marketing surveillance feed into ongoing risk-benefit assessments, helping to update drug safety profiles and ensure patient safety over the long term. In cases where unanticipated adverse reactions arise, preclinical data can be used to analyze and understand the mechanisms of action behind these reactions, providing the foundation for further safety measures, such as label changes, drug recalls, or additional clinical studies.



Fig 2: Post-Marketing Surveillance and Ongoing Monitoring

II. CONCLUSION:

The journey of a drug from development to market involves meticulous processes designed to ensure its safety and efficacy, with preclinical drug safety surveillance serving as a cornerstone in this endeavor. Preclinical safety testing provides the essential data needed to understand a drug's potential risks, toxicological effects, and safe dosage ranges, laying the groundwork for the subsequent clinical phases. This early-stage surveillance is vital, as it allows for the identification of potential hazards before a drug reaches human trials, setting the stage for effective clinical pharmacovigilance practices that monitor and manage the drug's safety profile as it progresses through clinical trials and eventually into post-marketing phases.

As the drug development process transitions from preclinical to clinical phases, the integration of preclinical safety data into clinical pharmacovigilance ensures that the safety of human participants is carefully monitored. In the clinical trials, particularly Phase I, the data obtained from animal models and in vitro studies

guide the safe escalation of doses and help manage adverse events (AEs) promptly. As clinical trials progress through Phases II and III, pharmacovigilance efforts expand to include monitoring larger and more diverse populations, identifying emerging safety concerns, and refining risk management strategies.

The role of global regulatory frameworks, such as those established by the WHO, ICH, FDA, and EMA, cannot be overstated. These organizations set internationally accepted guidelines for preclinical safety testing and pharmacovigilance, helping to standardize practices and ensure that safety assessments are conducted rigorously and consistently across the pharmaceutical industry. These frameworks also provide a structure for ongoing safety monitoring throughout a drug's lifecycle, adapting to emerging data and ensuring that drugs continue to meet safety standards even after they have been approved for public use.

REFERENCE:

[1]. World Health Organization (WHO). (2003). Pharmacovigilance: A tool for ensuring drug safety. WHO Technical Report Series, No. 929.
[2]. International Conference on Harmonisation (ICH). (1997). Guideline for Good Clinical Practice (E6).
[3]. U.S. Food and Drug Administration (FDA). (2019). Preclinical Safety Evaluation of Drug Candidates.FDA Guidelines.
[4]. European Medicines Agency (EMA). (2013). Guideline on the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
[5]. U.S. Food and Drug Administration (FDA). (2020). FDA's role in the drug approval process.
[6]. International Council for Harmonisation (ICH). (2009). S7A: Safety pharmacology studies.
[7]. International Council for Harmonisation (ICH). (2008). M3(R2): Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.
[8]. Food and Drug Administration (FDA). (2020). Genotoxicity testing for human pharmaceutical products: Considerations and approaches.
[9]. European Medicines Agency (EMA). (2015). Guideline on the clinical investigation of medicinal products in the pediatric population.
[10]. U.S. Food and Drug Administration (FDA). (2016). The FDA Drug Approval Process.Relevant section: Step-by-step explanation of the drug approval process, including safety testing (pages 11-15).
[11]. Van Norman, G. A. (2016). Drugs and Devices: Safety, FDA, and the Regulation of Medical Devices. Journal of the American College of Cardiology, 67(5), 557-570.
[12]. Bailey, M. A., & O'Connor, M. (2013). Safety assessment in the preclinical phase of drug development. Drug Safety, 36(5), 305-316.
[13]. Sullivan, H. W., & Rupp, M. E. (2020). Pharmacovigilance and risk management strategies in the clinical phase of drug development. Clinical Pharmacology & Therapeutics, 108(3), 538-546.
[14]. Crutchley, R. D., & Wager, L. A. (2017). Predicting adverse events: Preclinical studies and clinical pharmacovigilance. Toxicological Sciences, 158(2), 212-219.
[15]. Rochat, D. P., & O'Neill, P. M. (2014). The role of preclinical pharmacology in clinical pharmacovigilance. British Journal of Clinical Pharmacology, 78(5), 1031-1041.
[16]. Bertolotti, M., & Collins, K. P. (2015). Advances in safety pharmacology: Implications for preclinical testing. Regulatory Toxicology and Pharmacology, 73(1), 131-137.
[17]. Toxikon, Inc. (2016). The importance of preclinical safety testing in clinical pharmacovigilance: A review of toxicological data. Journal of Toxicology: Clinical Toxicology, 54(4), 294-303.
[18]. Sams-Dodd, F. (2013). The role of preclinical studies in the safety of new drug candidates. Regulatory Affairs Journal, 25(2), 15-20.
[19]. Lanza, D. L., & Kellogg, W. M. (2018). Integrating preclinical safety surveillance into post-marketing pharmacovigilance. The Journal of Clinical Pharmacology, 58(3), 385-392.
[20]. Matthews, H. L., & James, M. S. (2021). Pharmacovigilance: Safety surveillance in

clinical development. Therapeutic Advances in Drug Safety, 12(4), 1-11.

[21]. Pereira, D. M., & Ferreira, S. P. (2019). Toxicity testing in preclinical drug development: A review of regulatory approaches and challenges. Toxicology Reports, 6, 351-358.

[22]. Fuchs, C., & Garman, R. H. (2016). Nonclinical toxicology: Predicting the risk of adverse drug reactions in humans. Toxicology Letters, 259, 35-44.

[23]. Finkelstein, J. A., & Schulman, L. A. (2016). Preclinical safety testing in drug development. Nature Reviews Drug Discovery, 15(6), 335-336.

[24]. Baker, R. K., & Robinson, J. S. (2019). The importance of preclinical testing in drug development. Drug Safety, 42(5), 815-824.

[25]. Zhao, H., & Zhang, L. (2018). Preclinical pharmacokinetics and toxicity studies in drug discovery and development. Drug Metabolism Reviews, 50(4), 412-426.

[26]. Adverse Drug Reaction Committee. (2020). Pharmacovigilance in clinical trials and beyond: A regulatory perspective. Clinical Therapeutics, 42(7), 1230-1245.

[27]. Finkelstein, J. A., & Schulman, L. A. (2016). Preclinical safety testing in drug development. Nature Reviews Drug Discovery, 15(6), 335-336.

[28]. Baker, R. K., & Robinson, J. S. (2019). The importance of preclinical testing in drug development. Drug Safety, 42(5), 815-824.

[29]. Yuan, S. F., & Ding, D. (2018). Genotoxicity and carcinogenicity assessment in preclinical drug safety testing. Toxicology Research, 6(3), 387-396.

[30]. Zhao, H., & Zhang, L. (2018). Preclinical pharmacokinetics and toxicity studies in drug discovery and development. Drug Metabolism Reviews, 50(4), 412-42.

[31]. Sanguinetti, F., &Rivelli, A. (2019). Preclinical drug development: Key findings and challenges. Clinical Pharmacology & Therapeutics, 106(5), 913-920.